Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the ...
Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...
New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ...
DNA testing may inform treatment decisions and predict outcomes of adjuvant chemotherapy in patients with stage II-III colorectal cancer.
Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...
Medical Xpress on MSN5d
Blood test could guide use of celecoxib to reduce risk of colon cancer recurrence: StudyA data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...
CGP测试的结果能用于为晚期癌症治疗提供定制化的建议，其目的是为个体患者提供最有效的治疗选择从而延长其生存期。这项研究中，研究人员回归性地分析了在日本东北大学医学院个性化医学中心登记的219名晚期癌症患者的CGP和相关临床资料，在这些患者中，仅有14 ...
ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
In the study, ctDNA was first isolated from the plasma and CTCs were isolated and harvested using the Parsortix® system from a single blood tube taken from 27 lung cancer patients. CTCs and ctDNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback